Business Wire

St. Jude Medical Receives CE Mark for Industry's Only MR-Conditional Rechargeable Spinal Cord Stimulator Approved to Offer Burst Stimulation

Del

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced CE Mark approval for magnetic resonance imaging (MRI) conditional labeling for the company’s Prodigy MRI™ chronic pain system with select leads. Upon its launch, the Prodigy MRI system will become the market’s smallest MR-conditional rechargeable implantable pulse generator (IPG), as well as the industry’s sole MR-conditional SCS system capable of delivering both St. Jude Medical’s proprietary Burst stimulation and traditional tonic stimulation.

In addition to the approval of Prodigy MRI, all Octrode™ percutaneous and Penta™ 5-column paddle leads have received MR-conditional labeling and are approved for use with Prodigy MRI. The Penta lead is the industry’s only five-column paddle lead, which offers unmatched lateral coverage to finely control current and stimulate spinal nerves based specifically on patient need.

Nearly 95 million Europeans suffer from chronic pain, and the condition costs European health care systems a combined total of 300 billion Euro annually due to associated medical costs, lost work days and social security and welfare payments. SCS therapy can offer many patients meaningful pain relief and improvements in quality of life, yet for some patients the need for future MRI scans can act as a barrier to SCS therapy.

The new Prodigy MRI system will ensure patient access to St. Jude Medical’s innovative portfolio of chronic pain solutions, such as the company’s Burst stimulation, while maintaining the option for patients who may need future head and extremity MRI scans. In addition to the approval of the Prodigy MRI system, St. Jude Medical has announced plans to seek updated labeling in key markets around the world for additional chronic pain products, and plans to submit testing data to support full-body MR-conditional labeling for their future SCS systems.

“Clinical experience suggests that while relief from chronic pain remains the primary need for patients seeking spinal cord stimulation therapy, some patients who may benefit from SCS therapy may also need future MRI scans,” said Dr. Athanasios Koulousakis, Head of Department Functional Neurosurgery, Spasticity and Pain, University Hospital in Cologne, Germany. “So while the number of SCS patients requiring future MRIs may be limited, it is still critical to remove barriers to diagnostic options. Yet just as critical is providing MRI capability in SCS solutions that provide access to new therapy options, such as St. Jude Medical’s Burst stimulation. The new Prodigy MRI system helps put all such requirements into one package for our patients.”

St. Jude Medical is the only company approved to offer patients Burst stimulation, which the company introduced to the market in 2014 with the launch of the original Prodigy™ chronic pain system. The therapy was introduced after nearly a decade of research and study in collaboration with Dr. Dirk De Ridder, who filed the therapy’s initial patents in 2005.

The addition of Burst stimulation to St. Jude Medical’s chronic pain portfolio offered patients access to a therapy proven to relieve pain more effectively than traditional SCS while also significantly reducing or eliminating paresthesia for most patients. Clinical studies have also shown Burst stimulation can also offer pain relief to patients who may have become unresponsive to traditional SCS.

“MRI compatibility in our Prodigy system answers a growing market demand for devices that enhance patient access to new stimulation modes and therapy options,” said Eric S. Fain, M.D., group president of St. Jude Medical. “MRI compatibility for head and extremity will reduce treatment limitations or restrictions for chronic pain patients who may have future MRI needs. We want patients to have access to the most advanced therapies and technologies to effectively and safely reduce their chronic pain.”

About the St. Jude Medical Chronic Pain Portfolio

Chronic pain affects approximately 1.5 billion people worldwide, more than heart disease, cancer and diabetes combined. The condition can negatively impact personal relationships, work productivity and a patient’s daily routine. St. Jude Medical offers multiple solutions for patients to manage debilitating chronic pain, including spinal cord stimulation, targeted stimulation of the dorsal root ganglion (DRG) and radiofrequency ablation (RFA).

Spinal cord stimulation is a proven therapy used to manage chronic pain. SCS therapy uses a small implanted generator to deliver electrical pulses to the nerve fibers of the spinal column via thin wires, known as leads with electrodes. These electrical pulses mask or interrupt pain signals as they travel up the spinal cord to the brain, reducing pain sensation.

About Burst Stimulation

St. Jude Medical’s Burst stimulation is a proprietary neurostimulation waveform that functions independently from stimulation cycles and programming currently available from other SCS systems. Burst stimulation is engineered to mimic the natural firing patterns of the nerves in the body, and delivers closely-spaced pulses of electrical energy to a patient’s spinal cord to manage chronic pain. St. Jude Medical has led rigorous development and ongoing clinical study of Burst stimulation and is the only company approved to offer Burst therapy.

Burst stimulation may be an option for patients whose pain is not adequately controlled, or for those who lose therapeutic benefit over time with tonic SCS alone. Early research indicates that St. Jude Medical’s Burst stimulation may be able to deliver SCS therapy with reduced paresthesia, and may be more effective than tonic stimulation for some patients.

About St. Jude Medical

St. Jude Medical is a global medical device manufacturer dedicated to transforming the treatment of some of the world’s most expensive epidemic diseases. The company does this by developing cost-effective medical technologies that save and improve lives of patients around the world. Headquartered in St. Paul, Minn., St. Jude Medical has four major clinical focus areas that include cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com or follow us on Twitter @SJM_Media.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Annual Report on Form 10-K for the fiscal year ended January 3, 2015 and Quarterly Report on Form 10-Q for the fiscal quarter ended April 4, 2015. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

Contact information

St. Jude Medical, Inc.
Investor Relations
J.C. Weigelt, 651-756-4347
jweigelt@sjm.com
or
Media Relations
Barbara Van Buyten
Tel 32 2 774 67 12
bvanbuyten@sjm.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

IDEMIA and Octo Telematics Reinvent Car Sharing Experience by Adding Facial Recognition to EasyOpen Solution23.2.2018 15:57Pressemelding

IDEMIA, the global leader in Augmented Identity for an increasingly digital world, announces today that it has implemented facial recognition technology on EasyOpen, a solution previously developed with its partner Omoove, a wholly-owned Octo Telematics company, Europe’s leading Shared Mobility technology provider. The digital enrolment process combined with facial recognition technology will securely enroll and authenticate the driver before EasyOpen automatically opens the car. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180223005506/en/ (Photo: Idemia) You will never rent a car the same way thanks to EasyOpen solution that combines IDEMIA’s expertise in secure service enablement and Omoove’s experience in Shared Mobility platforms and on-board technology. The first version of the solution was launched last year and allows drivers, who have already registered on the application, to use their smartphones as a key to open

SM-Optics Unveils First FLEXSET Chip, Paving the Way to Optical Micro Nodes23.2.2018 14:00Pressemelding

SM-Optics launches FLEXSET, a single chip embedding multiple processing functionalities raising the bar for performances, density and architectural flexibility. The FLEXSET is the heart of the Lightmode product family. FLEXSET OTN switching matrix scales from 300Gbps to 1Tbps and can be addressed by ports spanning from traditional low-speed services like 2Mbps over micro-OTN, to layer2 and layer3 over ODUFlex, 100G over ODU4 and 200G over FlexO. Thanks to its embedded capabilities including multi-technology OAM, packet processing, synchronization and fast protection functions, FLEXSET operates by design at the lowest latency performances and features an Intel Stratix 10 FPGA. Following the launch of micro-OTN, a revolutionary approach to efficiently extend OTN protocol to low speed services, the launch of FLEXSET advances the vision of a highly interconnected metro network and of micro nodes. Revolving around functional block elements, micro nodes collapse in few rack units OTN and pho

Bitcoin Miner HashGains’ Crowdsale to Build Green Cloud Mining Data Centers Receives Excellent Response23.2.2018 13:56Pressemelding

HashGains.com, a leading cryptocurrency mining platform, has launched its crowdsale program to build mega cryptocurrency cloud mining data centers in India and Canada which uses renewable energy like wind and solar as source of energy. “With the growing worries around bitcoin mining causing environmental damage, difficulty levels of mining increasing and returns heading southwards, there was no better opportunity but to build green energy data centers which run on free sources of energy like wind and solar, ensuring handsome mining rewards while taking care of environment,” said Mr Anuj Bairathi, CEO & Founder, HashGains, who is crypto enthusiast himself. HashGains is a growing cloud mining platform with more than 10,000 active customers enjoying mining returns and is expected to reach the mark of 1 million customers by 2020. To handle such a massive growth and ever growing demand of customers, it becomes even more important that mega mining centers are planned which can serve needs of

Stratecast Recognizes CARDINALITY as a “10 to Watch in 2018”23.2.2018 13:07Pressemelding

In their new report, “Digital Transformation Means New Tools for New Business” —part of the Global Operations, Orchestration, Data Analytics, and Monetisation (ODAM) stream—Stratecast recognises CARDINALITY for their new approach towards processing big data to deliver applications such as Customer Experience, Operational Intelligence, Network Analytics, Churn Management and Marketing Intelligence. Stratecast identified that the CARDINALITY Perception Platform brings large amounts of data from multiple CSP sources together in order to address a growing group of data analysis needs from different operational work teams and the wider business. It also does this at ingestion rates and storage levels previously thought not practical. "Using design principals tied to microservices and containerized solution components, the platform is a major advancement in meeting CSP data analysis needs at a price untouchable by previously-defined platforms," said Karl Whitelock, Stratecast director of glo

IBC2018 Welcomes Channel 4’s Keith Underwood as Guest Chair of Content Steering Group23.2.2018 11:03Pressemelding

IBC is thrilled to announce that Keith Underwood, Director of Strategy and Technology at Channel 4, has accepted the role of Guest Chair of the Conference for IBC2018. The position involves acting as the figurehead and brand ambassador for IBC, setting the vision for the programme and increasing awareness and engagement with IBC across both traditional and converging media markets. Keith is the Channel 4 Executive Committee member responsible for strategy and corporate development, broadcast operations, content management, corporate systems and the development of Channel 4’s digital products. His achievements at the public broadcaster include the launch of All 4, Channel 4’s award-winning video on demand service that replaced 4oD in 2015. “The media industry is experiencing profound shifts in consumer behaviour, competitive dynamics, and technological innovation.” Keith Underwood said. “Relentless disruption of established business models presents new opportunities and challenges for p

SES S.A.: Full Year and Fourth Quarter 2017 Results23.2.2018 07:00Pressemelding

SES S.A. announced financial results for the year and three months ended 31 December 2017. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222006522/en/ Full Year and Fourth Quarter 2017 Results (Photo: Business Wire) Key financial highlights Reported revenue EUR 2,035.0 million, down 1.6% (-5.2% like-for-like(1)); SES Video -3.6%(1) and SES Networks -1.9%(1) EBITDA margin 65.1% (2016: 70.2% as reported and 66.7% like-for-like(1)) Net profit of EUR 596.1 million (2016: EUR 962.7 million including EUR 495.2 million gain related to O3b consolidation) Board is proposing 2017 dividend per A share of EUR 0.80 (2016: EUR 1.34) Change (%) Change (%) EUR million FY 2017 FY 2016 Reported Like-for-like (1) Q4 2017 Q4 2016 Reported Like-for-like (1) Revenue 2,035.0 2,068.8 -1.6% -5.2% 507.8 578.7 -12.2% -8.7% EBITDA 1,324.2 1,451.5 -8.8% -7.6% 329.6 390.6 -15.6% -12.2% EBITDA margin 65.1% 66.7%(1) 64.9% 67.6%(1) Operating profit (2) 6